Yahoo Web Search

Search results

    • Here's Why Eli Lilly Stock Remains a Screaming Buy

      Here's Why Eli Lilly Stock Remains a Screaming Buy

      Motley Fool via Yahoo Finance· 12 minutes ago

      Two of them -- donanemab and mirikuzumab -- already await regulatory approval. The U.S. Food and Drug Administration (FDA) plans to convene an advisory ...